Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options
OBJECTIVE: This study aimed to investigate the impact of the different therapy regimens used in multiple myeloma (MM) on bone-specific alkaline phosphatase (BALP) levels. METHODS: One hundred and thirteen patients with MM were included in the study. Patients were grouped according to the regimens th...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2014-12-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-38159 |
| _version_ | 1797912525393625088 |
|---|---|
| author | Güven Çetin Ahmet Emre Eşkazan M. Cem Ar Şeniz Öngören Aydın Burhan Ferhanoğlu Teoman Soysal Zafer Başlar Yıldız Aydın |
| author_facet | Güven Çetin Ahmet Emre Eşkazan M. Cem Ar Şeniz Öngören Aydın Burhan Ferhanoğlu Teoman Soysal Zafer Başlar Yıldız Aydın |
| author_sort | Güven Çetin |
| collection | DOAJ |
| description | OBJECTIVE: This study aimed to investigate the impact of the different therapy regimens used in multiple myeloma (MM) on bone-specific alkaline phosphatase (BALP) levels. METHODS: One hundred and thirteen patients with MM were included in the study. Patients were grouped according to the regimens they received, as follows: group 1, melphalan and prednisolone (MP); group 2, vincristine, adriablastin, and dexamethasone (VAD); group 3, thalidomide plus dexamethasone; and group 4, bortezomib plus dexamethasone. BALP levels were measured before treatment and at the third and sixth months of treatment. A fifth group consisted of patients in the post-treatment remission period at study entry (no-treatment group). RESULTS: The BALP levels at the third and sixth months of the treatment were significantly higher than the pre-treatment levels in the bortezomib and the no-treatment groups, whereas no significant difference was observed in the MP, VAD, and thalidomide groups. CONCLUSION: Considering that BALP is a surrogate marker of bone formation, our study suggests that bortezomib more efficiently leads to the improvement of bone disease in myeloma than other treatment options. |
| first_indexed | 2024-04-10T11:57:10Z |
| format | Article |
| id | doaj.art-919f0a5ffb474ffa9b555c63086aacdf |
| institution | Directory Open Access Journal |
| issn | 1308-5263 |
| language | English |
| last_indexed | 2024-04-10T11:57:10Z |
| publishDate | 2014-12-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-919f0a5ffb474ffa9b555c63086aacdf2023-02-15T16:16:47ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632014-12-0131437438010.4274/tjh.2013.0004TJH-38159Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy OptionsGüven Çetin0Ahmet Emre Eşkazan1M. Cem Ar2Şeniz Öngören Aydın3Burhan Ferhanoğlu4Teoman Soysal5Zafer Başlar6Yıldız Aydın7Bezmialem Vakıf University Faculty Of Medicine, Department Of Internal Medicine, Division Of Hematology, İstanbul, TurkeyDiyarbakır Training And Research Hospital, Clinic Of Hematology, Diyarbakır, Turkeyİstanbul Training And Research Hospital, Clinic Of Hematology, İstanbul, Turkeyİstanbul University Cerrahpaşa Faculty Of Medicine, Department Of Internal Medicine, Division Of Hematology, İstanbul, Turkeyİstanbul University Cerrahpaşa Faculty Of Medicine, Department Of Internal Medicine, Division Of Hematology, İstanbul, Turkeyİstanbul University Cerrahpaşa Faculty Of Medicine, Department Of Internal Medicine, Division Of Hematology, İstanbul, Turkeyİstanbul University Cerrahpaşa Faculty Of Medicine, Department Of Internal Medicine, Division Of Hematology, İstanbul, Turkeyİstanbul University Cerrahpaşa Faculty Of Medicine, Department Of Internal Medicine, Division Of Hematology, İstanbul, TurkeyOBJECTIVE: This study aimed to investigate the impact of the different therapy regimens used in multiple myeloma (MM) on bone-specific alkaline phosphatase (BALP) levels. METHODS: One hundred and thirteen patients with MM were included in the study. Patients were grouped according to the regimens they received, as follows: group 1, melphalan and prednisolone (MP); group 2, vincristine, adriablastin, and dexamethasone (VAD); group 3, thalidomide plus dexamethasone; and group 4, bortezomib plus dexamethasone. BALP levels were measured before treatment and at the third and sixth months of treatment. A fifth group consisted of patients in the post-treatment remission period at study entry (no-treatment group). RESULTS: The BALP levels at the third and sixth months of the treatment were significantly higher than the pre-treatment levels in the bortezomib and the no-treatment groups, whereas no significant difference was observed in the MP, VAD, and thalidomide groups. CONCLUSION: Considering that BALP is a surrogate marker of bone formation, our study suggests that bortezomib more efficiently leads to the improvement of bone disease in myeloma than other treatment options.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-38159multiple myelomabone-specific alkaline phosphatasebortezomibthalidomide |
| spellingShingle | Güven Çetin Ahmet Emre Eşkazan M. Cem Ar Şeniz Öngören Aydın Burhan Ferhanoğlu Teoman Soysal Zafer Başlar Yıldız Aydın Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options Turkish Journal of Hematology multiple myeloma bone-specific alkaline phosphatase bortezomib thalidomide |
| title | Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options |
| title_full | Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options |
| title_fullStr | Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options |
| title_full_unstemmed | Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options |
| title_short | Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options |
| title_sort | bone specific alkaline phosphatase levels among patients with multiple myeloma receiving various therapy options |
| topic | multiple myeloma bone-specific alkaline phosphatase bortezomib thalidomide |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-38159 |
| work_keys_str_mv | AT guvencetin bonespecificalkalinephosphataselevelsamongpatientswithmultiplemyelomareceivingvarioustherapyoptions AT ahmetemreeskazan bonespecificalkalinephosphataselevelsamongpatientswithmultiplemyelomareceivingvarioustherapyoptions AT mcemar bonespecificalkalinephosphataselevelsamongpatientswithmultiplemyelomareceivingvarioustherapyoptions AT senizongorenaydın bonespecificalkalinephosphataselevelsamongpatientswithmultiplemyelomareceivingvarioustherapyoptions AT burhanferhanoglu bonespecificalkalinephosphataselevelsamongpatientswithmultiplemyelomareceivingvarioustherapyoptions AT teomansoysal bonespecificalkalinephosphataselevelsamongpatientswithmultiplemyelomareceivingvarioustherapyoptions AT zaferbaslar bonespecificalkalinephosphataselevelsamongpatientswithmultiplemyelomareceivingvarioustherapyoptions AT yıldızaydın bonespecificalkalinephosphataselevelsamongpatientswithmultiplemyelomareceivingvarioustherapyoptions |